AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Is Vitura Health Overlooked in Australia’s Pharmaceuticals Market?
February 20, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights:,Shares have rebounded in recent weeks despite a steep decline over the previous year.,The price‐to‐sales metric remains considerably lower than that of many industry peers.,Revenue expansion has been moderate relative to the broader perfo...
Neurotech International Gains Key Regulatory Support for Rett Syndrome Drug
February 20, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,(ASX:NTI) secures a positive opinion from the European Medicines Agency for NTI164’s Orphan Medicinal Product Designation.,The US FDA granted orphan drug status to NTI164 in late 2024, signaling progress for the treatment’s potential appro...
Cochlear's (ASX:COH) Market Moves: Why This Healthcare Stock is on the Radar
February 20, 2025 12:00 AM AEDT| By Team Kalkine MediaHighlights,Cochlear (COH) stock has seen a 5.3% dip in 2025, drawing investor attention.,The healthcare sector remains a stable revenue generator, even during economic downturns.,Cochlear’s long-term growth outlook benefits from rising global healthc...
CardieX Limited Navigating the Path to Profitability
February 19, 2025 03:33 PM AEDT| By Team Kalkine MediaCardieX Limited Navigating the Path to Profitability
Fast-Track Approval Boosts Clarity Pharmaceuticals' Prostate Cancer Breakthrough
February 19, 2025 03:08 PM AEDT| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals secures fast-track approval for its prostate cancer drug.,The FDA’s decision accelerates development and market entry.,Cu-SAR-,bisPSMA,aims to enhance treatment options for advanced prostate cancer.,Clarity Pharmace...
Imagion Biosystems Moves Forward with FDA Application for MagSense HER2 Imaging Agent
February 19, 2025 02:09 PM AEDT| By Team Kalkine MediaHighlights,Imagion,Biosystems (IBX) progresses with FDA application for its,MagSense,HER2 imaging agent.,Phase 2 study aims to,optimize,dose and imaging protocol for improved diagnostic accuracy.,Recent capital funding of $3 million supports the next...
Will Clarity Pharmaceuticals' Imaging Agent Change Prostate Cancer Detection?
February 19, 2025 01:31 PM AEDT| By Team Kalkine MediaHighlights,FDA fast-track designation for prostate cancer imaging agent.,Innovation in dual-targeted bisPSMA technology developed in Australian laboratories.,Elevated market activity observed in the Australian biotech sector.,The biotechnology field...
Why Cyclopharm's (ASX:CYC) Cash Burn Isn't a Major Concern for Us
February 19, 2025 11:32 AM AEDT| By Team Kalkine MediaHighlights,Cyclopharm's cash reserves suggest a stable runway for growth.,Analyst forecasts indicate potential for cashflow breakeven soon.,Market capitalization analysis hints at feasible fundraising strategies.,Investors often find that even in cha...
Biocurious: As Mayne Pharmaceuticals faces a takeover bid, who might be next?
February 19, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Acquisition Momentum:,The agreement for Mayne Pharma to be acquired by Cosette has brought attention to the broader ASX biotech space, highlighting increased interest from global pharmaceutical companies.,Historical Perspective:,Previous...
How Are ASX-Listed Healthcare Companies Advancing Cancer Diagnostics and Treatments?
February 19, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Imagion Biosystems is leading the charge in cancer diagnostics with its MagSense platform for HER2+ breast cancer.,Noxopharm focuses on innovative treatments for glioblastoma through its Chroma platform.,Amplia and Invion are pioneering c...
Little Green Pharma Ltd (ASX:LGP) Recovery and Strategic Valuation in the Pharmaceuticals Sector
February 18, 2025 01:33 PM AEDT| By Team Kalkine MediaLittle Green Pharma Ltd (ASX:LGP) Recovery and Strategic Valuation in the Pharmaceuticals Sector
HMC Capital Considers Healthscope Acquisition with Focus on Workforce Stability
February 18, 2025 12:04 PM AEDT| By Team Kalkine MediaHighlights:,HMC Capital explores a potential acquisition of Healthscope, aiming to,maintain,operational stability.,The company,seeks,to minimise facility closures and job reductions as part of the deal.,HealthCo,Healthcare & Wellness REIT,discloses,d...
Health Check: Brokers Reduce Cochlear Valuations as Customers Delay Product Upgrades
February 18, 2025 11:00 AM AEDT| By Team Kalkine MediaBiotech Industry Update: Key Developments and Trials
Health Check: It's Time to Showcase Our Three Local Heroes
February 18, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Nanosonics prepares to introduce Coris, a new anti-infection device designed for hospital instrument cleaning.,Cogstate experiences revenue growth, driven by advancements in Alzheimer's disease clinical trials.,Sonic Healthcare reports pr...
Recce Pharmaceuticals Advances in Fight Against Skin Infections with Promising Phase II Trial Results
February 17, 2025 10:18 PM AEDT| By Team Kalkine MediaHighlights:,Positive results from Phase II trial of Recce 327 topical gel,No serious adverse events reported, meeting all safety and efficacy endpoints,Phase III trial for diabetic foot infections approved in Indonesia,Recce Pharmaceuticals (ASX:RCE)...
ASX Closes Lower as (ASX:AD8) Surges 26% and (ASX:BEN) Faces Sharp Decline
February 17, 2025 06:11 PM AEDT| By Team Kalkine MediaHighlights,(ASX:AD8) jumps 26% after strong half-year results,(,ASX:BEN,) slides 15% on weaker margins and earnings shortfall,Seven sectors end in the green, with Utilities leading gains,The Australian stock market wrapped up the trading session with...
Sonic Healthcare (ASX:SHL): A Closer Look at Stock Performance and Long-Term Outlook
February 17, 2025 04:17 PM AEDT| By Team Kalkine MediaHighlights,Sonic Healthcare (SHL) sees a 10% rise in,quarterly,share price.,Shareholder,return over the past three years shows a 23% decline.,Dividends contribute to a less negative total shareholder return (TSR) of -15%.,Sonic Healthcare (ASX:SHL),...
Recce Pharmaceuticals Shows Promising Results for Topical Gel in Treating Skin Infections, Sets Stage for Phase 3 Study
February 17, 2025 03:20 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals’ Phase II clinical trial of its topical gel, RECCE 327 (R327G), achieved a 93% primary efficacy endpoint in treating Acute Bacterial Skin and Skin Structure Infections, including Diabetic Foot Infections.,The gel demo...
Recce Pharmaceuticals (ASX:RCE) Advances R327G to Phase III After Positive Phase II Trial Results
February 17, 2025 01:12 PM AEDT| By Team Kalkine MediaHighlights:,93% Efficacy Rate:,Recce Pharmaceuticals (ASX:RCE) reported that R327G achieved a 93% primary efficacy endpoint in its Phase II trial for bacterial skin infections.,Phase III Progress:,The company is moving forward with Phase III registra...
Althea Group’s Expansion into the North American THC Beverage Market
February 17, 2025 12:30 PM AEDT| By Team Kalkine MediaCannabis in a Can: Nanocap Althea Secures $4M to Boost THC Beverage Expansion in the US and Canada
Advertise your brand on Kalkine Media